102396-29-2

Basic information

• Product Name: 6-chloro-5-methyl-2-(piperazin-1-yl)-N-(propan-2-yl)pyrimidin-4-amine
• Synonyms: 4-pyrimidinamine, 6-chloro-5-methyl-N-(1-methylethyl)-2-(1-piperazinyl)-
• CAS NO: 102396-29-2
• Molecular Formula: C₁₂H₂₀ClN₅
• Molecular Weight: 269.7737
• Mol File: 102396-29-2.mol

Chemical Properties

• Boiling Point: 458.7°C at 760 mmHg
• Flash Point: 231.2°C
• Density: 1.197g/cm³
• Vapor Pressure: 1.34E-08mmHg at 25°C
• Refractive Index: 1.576
• CAS DataBase Reference: 6-chloro-5-methyl-2-(piperazin-1-yl)-N-(propan-2-yl)pyrimidin-4-amine(CAS DataBase Reference)
• NIST Chemistry Reference: 6-chloro-5-methyl-2-(piperazin-1-yl)-N-(propan-2-yl)pyrimidin-4-amine(102396-29-2)
• EPA Substance Registry System: 6-chloro-5-methyl-2-(piperazin-1-yl)-N-(propan-2-yl)pyrimidin-4-amine(102396-29-2)

Safety Data

• Hazardous Substances Data: 102396-29-2(Hazardous Substances Data)

Usage

Uses

Used in Oncology:
6-chloro-5-methyl-2-(piperazin-1-yl)-N-(propan-2-yl)pyrimidin-4-amine is used as a kinase inhibitor for the treatment of cancer. It targets specific kinases involved in cancer cell proliferation and survival, potentially leading to the suppression of tumor growth and improved treatment outcomes for cancer patients.
Used in Combination Cancer Therapies:
6-chloro-5-methyl-2-(piperazin-1-yl)-N-(propan-2-yl)pyrimidin-4-amine may be used in combination with other cancer therapies to enhance treatment efficacy. Its potential synergistic effects with conventional chemotherapeutic drugs could improve chemo-sensitivity and overall outcomes in cancer treatment.

Upstream product

• 7556-55-0 1-formyl-4-methylpiperidine 
• 84727-78-6 4-(4,6-Dichloro-5-methyl-pyrimidin-2-yl)-piperazine-1-carbaldehyde 
• 84727-79-7 4-(4-Chloro-6-isopropylamino-5-methyl-pyrimidin-2-yl)-piperazine-1-carbaldehyde 

Relevant articles and documents

DERIVATIVES OF 2-PIPERAZINO-PYRIMIDINE, METHODS FOR THEIR PREPARATION AND THEIR UTILIZATION AS DRUGS OR INTERMEDIATES FOR DRUGS

Compounds are disclosed as useful as drugs or as intermediates for the manufacture of drugs, the compounds having the formula: STR1 in which X is hydrogen, chlorine, alkyl, alkoxy or alkylthio having 1 to 3 carbon atoms, R 2 is hydrogen or alkyl having 1 to 3 carbon atoms, Y 2 is chlorine and Y 1 is chlorine or STR2 in which R 1 is hydrogen, straight or branched chain alkyl having 1 to 7 carbon atoms, cycloalkyl having 3 to 7 carbon atoms or cycloalkylalkyl having 4 to 8 carbon atoms, or Y 2 and Y 1 are both OH. Also disclosed are methods for preparation of the compounds.